Alto Neuroscience Inc ANRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Trading Information
- Previous Close Price
- $27.12
- Day Range
- $24.79–27.12
- 52-Week Range
- $12.51–37.48
- Bid/Ask
- $21.00 / $27.83
- Shares Outstanding
- 40.11M
- Market Cap
- $999.16M
- Volume/Avg
- 498,677 / 600,278
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 68
Valuation
Metric | ANRO |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.36 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ANRO |
|---|---|
Quick Ratio | 17.90 |
Current Ratio | 18.12 |
Interest Coverage | −48.67 |
Quick Ratio
ANRO
Profitability
Metric | ANRO |
|---|---|
Return on Assets (Normalized) | −35.05% |
Return on Equity (Normalized) | −40.77% |
Return on Invested Capital (Normalized) | −39.15% |
Return on Assets
ANRO
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|&r%%j@ | LOCK|X<vj | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|MkSVc> | LOCK|qR%# | $99B | |||
| Moderna Inc MRNA | LOCK|^g$MXg | LOCK|$Ck | $84B | |||
| argenx SE ADR ARGX | LOCK|%pK%S@g | LOCK|XC | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|%fg<R? | LOCK|$K? | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|?%c<^hy | LOCK|ZZ%gC | $31B | |||
| Incyte Corp INCY | LOCK|QB><>!? | LOCK|%J% | $24B | |||
| BioNTech SE ADR BNTX | LOCK|mp^$yK# | LOCK|n!M | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|#D&L&Ks | LOCK|D$<Fn | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|g%?#xn^ | LOCK|w>! | $15B |